Straumann® Biomaterials Straumann® Emdogain® Orchestrating ...€¦ · – Periodontal ligament...
Transcript of Straumann® Biomaterials Straumann® Emdogain® Orchestrating ...€¦ · – Periodontal ligament...
ESTHETIC DENTISTRY
Straumann® Biomaterials
Straumann® Emdogain®Orchestrating periodontal regeneration.
At a glance
Summary
Straumann® Emdogain®
Clinical evidence
How it works
What’s in it for you?
Technical information
Clinical cases
What leading experts say
At a glance
• Gel containing Enamel Matrix Derivative
• Promotes true periodontal regeneration¹ of the:
– Cementum – Periodontal ligament – Alveolar bone
• Indications: – Intrabony defects – Recession defects – Furcation defects
1 Miron RJ, Sculean A, Cochran DL, Froum S, Zucchelli G, Nemcovsky C, Donos N, Lyngstadaas SP, Deschner J, Dard M, Stavropoulos A, Zhang Y, Trombelli L, Kasaj A, Shirakata Y, Cortellini P, Tonetti M, Rasperini G, Jepsen S, Bosshardt DD. Twenty years of enamel matrix derivative: the past, the present and the future. J Clin Periodontol 2016; doi: 10.1111/jcpe.12546
At a glance
Straumann® Emdogain® in statistics:
1 McGuire MK, Scheyer ET, Nunn M. Evaluation of human recession defects treated with coronally advanced flaps and either enamel matrix derivative or connective tissue: com-parison of clinical parameters at 10 years. J Periodontol. 2012 Nov;83(11):1353-62 / 2 Sculean A, et al. Ten-year results following treatment of intrabony defects with enamel ma-trix proteins and guided tissue regeneration. J Clin Periodontol. 2008 Sep;35(9):817-24
* Based on the number of syringes sold to date, globally
** According to PUBMED search for “Emdogain” or “enamel matrix derivative”
*** Based on a global post-surgical complicationcomplication rate of less than 0.002 %
> 20 years on the market
> 2 million patients treated*
> >
600 clinical & 1,000 scientific publications**
Extremely well tolerated***
Stable results documented
over 10 years in 2 indications¹²
• Improved and predictable clinical results
• Patient satisfaction
• Less complications
What’s in it for you?
30
20
10
0
40
What’s in it for you?
Improved and predictable results in intrabony defects¹
Almost 2× as many defects achieve ≥ 4 mm CAL (Clinical Attachment Level) gain after 1 year
1 Tonetti MS, Lang NP, Cortellini P, Suvan JE, Adriaens P, Dubravec D, Fonzar A, Fourmousis I, Mayfield L, Rossi R, Silvestri M, Tiedemann C, Topoll H, Vangsted T, Wallkamm B.Enamel matrix proteins in the regenerative therapy of deep intrabony defects. J Clin Periodontol. 2002 Apr;29(4):317-25
Percentage of patients with highly significant outcome (CAL gain of > 4 mm) 1 year post-operative in the treatment of intrabony defects
% of patients
■ Open Flap Debridement (OFD)
■ Open Flap Debridement with Straumann® Emdogain®
75%
50 %
25%
0 %
100 %
CAFCAF with Emdogain®
75%
50 %
25%
0 %
100 %
CAFCAF with Emdogain®
75%
50 %
25%
0 %
100 %
CAFCAF with Emdogain®
75%
50 %
25%
0 %
100 %
CAFCAF with Emdogain®
What’s in it for you?
Improved and predictable results in recession defects¹
CAF (Coronally Advanced Flap) + Emdogain® achieves 40 % more root coverage than CAF alone.
Percentage of complete root coverage 18 months after surgery
1 Pilloni A, Paolantonio M, Camargo PM. Root coverage with a coronally positioned flap used in combination with enamel matrix derivative: 18-month clinical evaluation. J Periodontol. 2006 Dec;77(12):2031-9.
CAF with Emdogain® CAF
Thanks to:
• Tooth preservation
• Improved esthetics
• Less post-surgical pain and swelling
What’s in it for you?
Patient satisfaction
What’s in it for you?
Patient satisfaction thanks to less pain and swelling• Reduce post-surgical inflammation of oral surgical procedures
5⊗more patients without
pain after 1 week
7⊗more patients without swelling after 1 week
• In case of recession coverage, Straumann® Emdogain® obviates the need for an autologous connective tissue graft, a painful procedure
Less complications compared to surgeries involving membranes¹
What’s in it for you?
Less complications
1 Sanz M, Tonetti MS, Zabalegui I, Sicilia A, Blanco J, Rebelo H, Rasperini G, Mer-li M, Cortellini P, Suvan JE. Treatment of intrabony defects with enamel matrix proteins or barrier membranes: results from a multicenter practice-based clini cal trial.J Periodontol. 2004 May;75(5):726-33.
toot
h ro
ot ra
dice
del
den
te ra
cine
de
la d
ent
How it works
Intrabony defect
Alveolar bone
Straumann® Emdogain® is applied and forms a matrix on the root surface.
Mesenchymal stem cells are attracted to the site and proliferate.
The cells secrete specific cyto-kines and autocrine substances.
Cells differentiate into cementoblasts.
The newly formed cementum increases in thickness and the periodontal fibers are anchored in it.
Within months, the periodontal ligament is formed.
Bone grows in the defect. The entire periodontium has been regenerated.
Toot
h ro
ot
Technical informationSINGLE PACKS
075.127W Straumann® Emdogain® 0.15 ml Singlepack
075.101W Straumann® Emdogain® 0.3 ml Singlepack
075.102W Straumann® Emdogain® 0.7 ml Singlepack
MULTIPACKS (3 × Straumann® Emdogain® + 3 × PrefGel®)
075.114W Straumann® Emdogain® 0.3 ml Multipack
075.116W Straumann® Emdogain® 0.7 ml Multipack
5-PACKS
075.098W Straumann® Emdogain® 0.15 ml 5-Pack
PREFGEL®
075.203W PrefGel® 0.6 ml, 5-Pack
Prof. Dr. Giovanni Zucchelli, University of Bologna, Italy
“Because Emdogain® improves soft tissue healing, it …”
Prof. Dr. Andrea Mombelli, University of Geneva, Switzerland
“The advantage of using a product which is 20 years old …”
Prof. Dr. Miron Weinreb, Tel Aviv University, Israel
“Emdogain® improves healing of oral mucosa incisional …”
Prof. Dr. David Cochran, University of Texas Health Science Center San Antonio, USA
“Straumann® Emdogain® stimulates …”
What leading experts say
The advantage of using a product which is 20 years old is that we know the product and we know that it is safe.
What leading experts say
Prof. Dr. Andrea Mombelli, University of Geneva, Switzerland
Straumann® Emdogain® stimulates the regeneration of both the hard and soft tissues of the periodontium at the same time. Every time I expose a tooth root surface in a patient, I apply Emdogain® to stimulate cementum formation. I have nothing to lose and a lot to gain.
What leading experts say
Prof. Dr. David Cochran, University of Texas Health Science Center San Antonio, USA
Because Emdogain® improves soft tissue healing, it helps me meet the high expectations of my patients in terms of esthetics.
What leading experts say
Prof. Dr. Giovanni Zucchelli, University of Bologna, Italy
Emdogain® improves healing of oral mucosa incisional wounds by promoting different biological events occurring during healing.
What leading experts say
Prof. Dr. Miron Weinreb, Tel Aviv University, Israel
• Long-term clinical evidence in intrabony defects
• Long-term clinical evidence in recession defects
• Clinical evidence in furcation defects
• Less complications compared to membranes
• Human histological evidence of true regeneration – recession defects
Clinical evidence
* S CAL gain between OFD and all other
after 1 year
after 10 years
0
CAL gain (mm)
2.01.8
3.2
2.8
3.3
2.9
3.4
2.9
EMD = Straumann® ®Emdogain
GTR = Guided Tissue Regeneration (membrane)
OFD = Open Flap Debridement alone
EMD
OFD
*
GTR
EMD
GTR
1.0
2.0
3.0
4.0
treatments approaches
tatistically significant difference in
* S CAL gain between OFD and all other
after 1 year
after 10 years
0
CAL gain (mm)
2.01.8
3.2
2.8
3.3
2.9
3.4
2.9
EMD = Straumann® ®Emdogain
GTR = Guided Tissue Regeneration (membrane)
OFD = Open Flap Debridement alone
EMD
OFD
*
GTR
EMD
GTR
1.0
2.0
3.0
4.0
treatments approaches
tatistically significant difference in
Clinical evidence
Long-term clinical evidence in intrabony defects¹
Study Design Randomized, controlled, prospective, single-center study
Population 38 patients, defects with probing depth of > or = 6 mm and intrabony component > 3 mm
Modalities Open flap debridement (OFD)
Emdogain®
Membrane
Emdogain® + membrane
Duration Regular maintenance program (4 times per year)
Results Significantly higher clinical attachment level (CAL) gain with Emdogain® compared with OFD
Clinical results can be maintained over 10 years
Adding a membrane to Emdogain® does not improve the result
1 Sculean A, et al. Ten-year results following treatment of intra-bony defects with enamel matrix proteins and guided tissue regeneration. J Clin Periodontol. 2008 Sep;35(9):817-24
* S CAL gain between OFD and all other
after 1 year
after 10 years
0
CAL gain (mm)
2.01.8
3.2
2.8
3.3
2.9
3.4
2.9
EMD = Straumann® ®Emdogain
GTR = Guided Tissue Regeneration (membrane)
OFD = Open Flap Debridement alone
EMD
OFD
*
GTR
EMD
GTR
1.0
2.0
3.0
4.0
treatments approaches
tatistically significant difference in
CAL gain (mm)
* Statistically significant difference in CAL gain between OFD and all other
treatments approaches
after 1 year
after 10 years
5
mm
Baseline 1 year 10 years
4
3
2
1
0 * **
*
CTG + CAF
* Significant difference from baseline
Values in figures show mean actual levels at each time point
Emdogain® + CAFEmdogain® + CAF CTF + CAF
Clinical evidence
Long-term clinical evidence in recession defects¹
Study Design Randomized, controlled, split mouth, single-center study
Population 9 patients with Miller class I or II recession defects (Baseline recession ≥ 4 mm with ≤ 2.5 mm keratinized tissue)
Modalities Coronally Advanced Flap (CAF) + Emdogain®
CAF + Connective Tissue Graft (CTG)
Results Both treatments show stable, clinically effective outcomes
No significant difference between the two treatments at 10 years
Patients satisfaction with the treatment is higher for Emdogain®
Emdogain® is a viable alternative to CTG and can avoid complications associated with donor site surgery
1 McGuire MK, Scheyer ET, Nunn M. Evaluation of human recession defects treated with coronally advanced flaps and either enamel matrix derivative or connective tissue: comparison of clinical parameters at 10 years. J Periodontol. 2012 Nov;83(11):1353-62
* Significant difference from baseline
Recession depth
mm Values in figures show mean actual levels at each time point
3
2
1
0
mm
2.8
1.8
Membrane Emdogain®
p = 0.033
Clinical evidence
Clinical evidence in furcation defects¹
Study Design Randomized, controlled, prospective, split-mouth, multi-center clinical trial
Population 45 patients with contralateral furcations (90 furcations in total)
Modalities Emdogain®
Collagen membrane
Results Significantly greater reduction in horizontal furcation depth with Emdogain®
Lower incidence of pain and swelling when Emdogain® was used
(at re-entry at 14 months post-op)
Median reduction of horizontal furcation with interquartile interval
1 A randomized clinical trial comparing enamel matrix derivative and membrane treatment of buccal Class II furcation involvement in mandibular molars. Part I: Study design and results for primary outcomes. Jepsen S, Heinz B, Jepsen K, Arjomand M, Hoffmann T, Richter S, Reich E, Sculean A, Gonzales JR, Bödeker RH, Meyle J. J Periodontol. 2004 Aug;75(8):1150-60.
Membrane Emdogain®
1w 2w 3w
0
10
20
30
40
50
60
70
80
29%35%
62%
GTR Emdogain®
0
20
40
60
80
100
6%
100%
Clinical evidence
Less complications compared to membranes¹
Study Design Randomized, controlled, prospective, multi-center clinical trial
Population 75 patients, each with at least 1 intrabony defect of ≥ 3 mm
Modalities Emdogain®
Collagen membrane
Results Both treatment modalities performed similarly
All sites treated with a membrane had a complication, either 1, 2 or 3 weeks after treatment whereas only 6 % had such issues in the Emdogain® group
Rate of appearance of membrane exposure in GTR after 1, 2 and 3 weeks in the GTR group
Complication rate (lack of primary closure, flap dehiscence, membrane exposure, suppuration) after 9 weeks with GTR or Straumann® Emdogain®1 Sanz M, Tonetti MS, Zabalegui I, Sicilia A, Blanco J, Rebelo H, Rasperini G, Merli M, Cortellini P,
Suvan JE. Treatment of intrabony defects with enamel matrix proteins or barrier membranes: results from a multicenter practice-based clinical trial. J Periodontol. 2004 May;75(5):726-33.
1w 2w 3w
0
10
20
30
40
50
60
70
80
29%35%
62%
CTG+CAF Emdogain®+ CAF
78%
0%0
20
40
60
80
100
Percentage of teeth with regeneration*
CTG+CAF Emdogain®+ CAF
78%
0%0
20
40
60
80
100
Percentage of teeth with regeneration*
CTG+CAF Emdogain®+ CAF
78%
0%0
20
40
60
80
100
Percentage of teeth with regeneration*
Clinical evidence
Human histological evi-dence of true regeneration – recession defects¹
Study Design Randomized, open-label study
Population 3 patients, 12 teeth
Modalities Emdogain® + Coronally Advanced Flap (CAF)
Connective Tissue Graft (CTG) + CAF
Results Regeneration* in all three patients in the Emdogain® + CAF group
Lack of regeneration** in all three patients in the CTG + CAF group
*formation of new cementum, periodontal ligament and bone**formation of long junction epithelium
1 McGuire MK, Scheyer ET, Schupbach P. A Prospective, Cased-Controlled Study Evaluating the use of Enamel Matrix Derivative on Human Buccal Recession Defects: A Human Histologic Examination. J Periodontol. 2016 Feb 1:1-34.
Dr. Gunnar HedenKarlstadt, Sweden
Prof. Dr. Giovanni ZucchelliUniversity of Bologna, Italy
Dr. David NisandParis, France
Clinical cases
Pictures courtesy of Dr. Gunnar Heden, Karlstadt, Sweden
Pre-op 8 years post-op
Clinical cases
Dr. Gunnar Heden – Long-term clinical case in intrabony defects
Pictures courtesy of Prof. Giovanni Zucchelli, University of Bologna, Italy
8 months post-treatment with CAF and Emdogain®
7 years post-treatment with CAF and Emdogain®
Before treatment
Clinical cases
Prof. Dr. Giovanni Zucchelli – Long-term clinical case in gum recession defects
Pictures courtesy of Dr. David Nisand, Paris, France
Pre-op 2 years post-op
Clinical cases
Dr. David Nisand – Long-term clinical case in furcation defects
Using Straumann® Emdogain®
• Helps achieving predictable results in your periodontal surgery and recession coverage procedures
• Leads to patient satisfaction thanks to better tooth prognosis, less pain and swelling and to esthetic results
• Shows less complications compared to membranes
Summary
490.
147/
en/B
/00
11/
19